Everyone Is Talking About JAK Inhibitors: Addressing Safety in Dermatology
Time: 10:30 am
day: Pre-Conference Workshops
Details:
As JAK inhibitors bring a level of efficacy unseen previously for Atopic Dermatitis, and Incyte’s Phase II in Hidradenitis Suppurativa reinforce the safety of the selective JAK1/ JAK2 inhibitor topical cream, is this enough to overcome the black box warning of 2021, or are dermatologists still wary of using this modality due to safety concerns?
This workshop will gather experts to discuss:
- As the JAK inhibitor pipeline grows, what dermatology-specific challenges need to be overcome?
- How are toxicity concerns being addressed, and is this impacting access to potential interventions with superior efficacy?
- How do dermatologists view JAK inhibitors and their place in inflammatory disease treatment paradigms?
Gain many stakeholder perspectives, as this workshop presents an evolving therapeutic landscape, and projections for the future role of JAK inhibitors, for improving long-term patient outcomes in dermatology.
Featuring a Case Study from Lynk Pharmaceuticals: Efficacy & Safety of LNK01001 in Chinese Patients with Moderate to Severe Atopic Dermatitis: Results from a 12-week Phase 2 Trial – Download the Event Guide to Learn More.
